Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial

Movement Disorders

Volumn 21, Issue 10, 2006, Pages 1614-1617

  Ondo, William G ^a,b   Silay, Yavuz S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Benzodiazepine antagonist; Flumazenil; GABA; Parkinson's disease

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; LEVODOPA; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; LEG PAIN; MALE; MOTOR PERFORMANCE; OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; BASAL GANGLIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUMAZENIL; GABA ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOTOR SKILLS; PARKINSON DISEASE; REACTION TIME;

EID: 33750993734     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21022     Document Type: Article

References (29)

1. Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 2001;22:188-194.
2. Dawson GR, Collinson N, Atack JR. Development of subtype selective GABAA modulators. CNS Spectr 2005;10:21-27.
3. Rowlett JK, Cook JM, Duke AN, Platt DM. Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. CNS Spectr 2005;10:40-48.
4. Hunkeler W, Mohler H, Pieri L, et al. Selective antagonists of benzodiazepines. Nature 1981;290:514-516.
5. Rothstein JD, Guidotti A, Costa E. Release of endogenous benzodiazepine receptor ligands (endozepines) from cultured neurons. Neurosci Lett 1992;143:210-214.
6. Ruscito BJ, Harrison NL. Hemoglobin metabolites mimic benzodiazepines and are possible mediators of hepatic encephalopathy. Blood 2003;102:1525-1528.
7. Heniff MS, Moore GP, Trout A, Cordell WH, Nelson DR. Comparison of routes of flumazenil administration to reverse midazolam-induced respiratory depression in a canine model. Acad Emerg Med 1997;4:1115-1118.
8. Scheepers LD, Montgomery CJ, Kinahan AM, Dunn GS, Bourne RA, McCormack JP. Plasma concentration of flumazenil following intranasal administration in children. Can J Anaesth 2000;47:120-124.
9. Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist [published erratum appears in Drugs 1992;43:442]; Drugs 1991;42:1061-1089.
10. Persson A, Ehrin E, Eriksson L, et al. Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatr Res 1985;19: 609-622.
11. Samson Y, Hantraye P, Baron JC, Soussaline F, Comar D, Maziere M. Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. Eur J Pharmacol 1985; 110:247-251.
12. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:142-151.
13. Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord 2003;18:683-685.
14. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999;14:572-584.
15. Vila M, Herrero MT, Levy R, et al. Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 1996;46:802-809.
16. Guridi J, Herrero MT, Luquin MR, et al. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996; 119(Pt 5):1717-1727.
17. Scatton B, Lehmann J. N-methyl-C-aspartate-type receptors mediate striatal 3H-acetylcholine release evoked by excitatory amino acids. Nature 1982;297:422-424.
18. Finlay JM, Damsma G, Fibiger HC. Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology 1992;106:202-208.
19. Brose N, O'Neill RD, Boutelle MG, Fillenz M. Dopamine in the basal ganglia and benzodiazepine-induced sedation. Neuropharmacology 1988;27:589-595.
20. Bartholini G, Stadler H. Evidence for intrastriatal GABAergic influence on doparninergic neurons in the cat. Neuropharmacology 1977;16:343-347.
21. Motzo C, Porceddu ML, Dazzi L, Sanna A, Serra M, Biggio G. Enhancement by flumazenil of dopamine release in the nucleus accumbens of rats repeatedly exposed to diazepam or imidazenil. Psychopharmacology 1997;131:34-39.
22. Nakano T, Kobayashi K, Hosoi R, et al. Effects of the GABAergic system on in vivo binding of [3H]N-methylspiperone. Neuropharmacology 1998;37:375-381.
23. Lloyd KG. The influence of GABA on dopamine neuron activity. In: Langer Z, Starke L, Dubocovitch ML, editors. Presynaptic receptors. New York: Pergamon Press; 1979. p 207-212.
24. Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol 1995;37:776-783.
25. Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32: 749-757.
26. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992;32:151-161.
27. Samuel M, Ceballos-Baumaum AO, Turjanski N, et al. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study. Brain 1997;120(Pt 8):1301-1313.
28. Kawabata K, Tachibana H. [Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I-iomazenil SPECT]. Nippon Rinsho - Jpn J Clin Med 1997;55:244-248.
29. Palmieri MG, Iani C, Scalise A, et al. The effect of benzodiazepines and flumazenil on motor cortical excitability in the human brain. Brain Res 1999;815:192-199.